MarketCap
Facebook
X
Telegram
Tyme Technologies Total Current Liabilities | TYME
Annual Total Current Liabilities Tyme Technologies
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.39 M | 5.64 M | 5.58 M | 6.21 M | 4.55 M | 3.33 M | 1.91 M | 1.47 M | 2.64 M | 42.6 K | 2 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 7.39 M | 2 K | 3.52 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
43.3 B | $ 263.04 | 0.49 % | $ 465 B |  USA |
 |
AbCellera Biologics
ABCL
|
64.3 M | $ 11.41 | 2.15 % | $ 3.41 B |  Canada |
 |
Фармсинтез
LIFE
|
1.02 B | - | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
28.6 M | $ 5.53 | 6.02 % | $ 678 M | USA |
 |
ADC Therapeutics SA
ADCT
|
70.2 M | $ 1.09 | 3.74 % | $ 139 M |  Schweiz |
 |
Evelo Biosciences
EVLO
|
12.4 M | - | -14.46 % | $ 27.9 M | USA |
 |
Allakos
ALLK
|
17.8 M | - | - | $ 28.6 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | USA |
 |
Clovis Oncology
CLVS
|
125 M | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
23.9 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
16.1 M | - | - | $ 401 M | USA |
 |
ADMA Biologics
ADMA
|
69.5 M | $ 8.61 | 0.16 % | $ 2.05 B | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
53.3 M | - | -9.21 % | $ 2.55 M | USA |
 |
89bio
ETNB
|
36.1 M | - | - | $ 1.55 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
31 M | - | - | $ 384 M |  Britain |
 |
Fusion Pharmaceuticals
FUSN
|
16.2 M | - | - | $ 1.41 B | Canada |
 |
Guardion Health Sciences
GHSI
|
1.32 M | - | -0.31 % | $ 3.64 M | USA |
 |
Genocea Biosciences
GNCA
|
18.7 M | - | -15.0 % | $ 3.04 M | USA |
 |
Gritstone Oncology
GRTS
|
27.3 M | - | 0.42 % | $ 213 M | USA |
 |
G1 Therapeutics
GTHX
|
29.7 M | - | - | $ 370 M | USA |
 |
Harpoon Therapeutics
HARP
|
52.4 M | - | - | $ 763 M | USA |
 |
Humanigen
HGEN
|
56.2 M | - | -81.12 % | $ 4.28 M | USA |
 |
HOOKIPA Pharma
HOOK
|
24.7 M | - | -6.92 % | $ 79.4 M | USA |
 |
Intercept Pharmaceuticals
ICPT
|
230 M | - | - | $ 643 M | USA |
 |
IGM Biosciences
IGMS
|
37.6 M | - | - | $ 76.9 M | USA |
 |
Intra-Cellular Therapies
ITCI
|
206 M | - | - | $ 13.6 B | USA |
 |
Kinnate Biopharma
KNTE
|
12 M | - | - | $ 123 M | USA |
 |
Chinook Therapeutics
KDNY
|
50.8 M | - | - | $ 2.6 B | USA |
 |
Kaleido Biosciences
KLDO
|
29.7 M | - | -3.69 % | $ 12.4 M | USA |
 |
Kronos Bio
KRON
|
15.3 M | - | 1.49 % | $ 50.8 M | USA |
 |
Karuna Therapeutics
KRTX
|
68.1 M | - | - | $ 12.2 B | USA |
 |
Landos Biopharma
LABP
|
6.25 M | - | 0.58 % | $ 144 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
17.6 M | - | - | $ 154 M | USA |
 |
LogicBio Therapeutics
LOGC
|
19.6 M | - | - | $ 229 M | USA |
 |
Lumos Pharma
LUMO
|
7.03 M | - | - | $ 35.3 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
441 K | - | - | $ 216 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
10.8 M | - | - | $ 23.9 M | USA |
 |
Mirati Therapeutics
MRTX
|
159 M | - | - | $ 3.3 B | USA |
 |
NexImmune
NEXI
|
5.08 M | - | 70.13 % | $ 4.12 M | USA |
 |
9 Meters Biopharma
NMTR
|
30.7 M | - | -42.97 % | $ 1.05 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
2.47 M | - | -37.48 % | $ 476 K | USA |
 |
Oncorus
ONCR
|
37.2 M | - | -8.54 % | $ 3.19 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
6.63 M | - | 31.87 % | $ 1.61 M | USA |
 |
Oncternal Therapeutics
ONCT
|
5.2 M | - | -24.12 % | $ 1.56 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
6.85 M | - | - | $ 109 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
60.6 M | - | 1.02 % | $ 90.8 M | Britain |